CRISPR Therapeutics (NASDAQ:CRSP) Given Overweight Rating at Piper Sandler

Piper Sandler reissued their overweight rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research note issued to investors on Friday,Benzinga reports. They currently have a $105.00 price target on the stock.

CRSP has been the topic of a number of other reports. Chardan Capital reissued a “buy” rating and set a $82.00 price target on shares of CRISPR Therapeutics in a report on Thursday. JMP Securities reissued a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday. Wall Street Zen raised CRISPR Therapeutics to a “sell” rating in a report on Friday, May 16th. Barclays reduced their target price on CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating on the stock in a report on Friday, May 9th. Finally, The Goldman Sachs Group reduced their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating on the stock in a report on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $71.75.

CRISPR Therapeutics Stock Up 1.7%

NASDAQ:CRSP opened at $47.49 on Friday. The business’s 50-day simple moving average is $39.48 and its two-hundred day simple moving average is $40.55. The stock has a market cap of $4.10 billion, a PE ratio of -10.51 and a beta of 1.75. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $63.68.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. The firm’s revenue for the quarter was up 71.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.43) EPS. Sell-side analysts anticipate that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the sale, the insider now directly owns 6,068 shares in the company, valued at approximately $218,083.92. The trade was a 39.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Intellectus Partners LLC increased its holdings in shares of CRISPR Therapeutics by 3.6% during the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after purchasing an additional 250 shares in the last quarter. Farrow Financial Inc. lifted its stake in shares of CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock valued at $777,000 after purchasing an additional 270 shares during the period. SFE Investment Counsel boosted its stake in shares of CRISPR Therapeutics by 5.8% during the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company’s stock worth $221,000 after acquiring an additional 355 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of CRISPR Therapeutics by 7.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock worth $215,000 after acquiring an additional 372 shares in the last quarter. Finally, Axxcess Wealth Management LLC boosted its stake in shares of CRISPR Therapeutics by 4.0% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company’s stock worth $351,000 after acquiring an additional 393 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.